Financials MeVis Medical Solutions AG
Equities
M3V
DE000A0LBFE4
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.4 EUR | +0.76% | +2.33% | +4.76% |
Valuation
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 62.61 | 54.24 | 57.88 | 59.33 | 62.24 | 51.69 |
Enterprise Value (EV) 1 | 59.13 | 51.63 | 53.92 | 51.71 | 52.92 | 43.94 |
P/E ratio | 8.73 x | 6.72 x | 10.1 x | 13.1 x | 7.99 x | 10.5 x |
Yield | - | - | - | - | - | 3.35% |
Capitalization / Revenue | 3.74 x | 3 x | 3.38 x | 3.66 x | 3.32 x | 2.98 x |
EV / Revenue | 3.53 x | 2.86 x | 3.15 x | 3.19 x | 2.82 x | 2.53 x |
EV / EBITDA | 7.97 x | 6.99 x | 8.94 x | 13.2 x | 8.07 x | 8.86 x |
EV / FCF | -11.3 x | 15.1 x | 59.1 x | 6.22 x | 19.3 x | 10.3 x |
FCF Yield | -8.88% | 6.63% | 1.69% | 16.1% | 5.19% | 9.73% |
Price to Book | 1.95 x | 3.04 x | 3.25 x | 3.33 x | 3.49 x | 2.9 x |
Nbr of stocks (in thousands) | 1,820 | 1,820 | 1,820 | 1,820 | 1,820 | 1,820 |
Reference price 2 | 34.40 | 29.80 | 31.80 | 32.60 | 34.20 | 28.40 |
Announcement Date | 30/01/19 | 29/01/20 | 28/01/21 | 27/01/22 | 26/01/23 | 20/02/24 |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 16.76 | 18.07 | 17.13 | 16.21 | 18.76 | 17.34 |
EBITDA 1 | 7.422 | 7.39 | 6.03 | 3.929 | 6.559 | 4.96 |
EBIT 1 | 6.869 | 7.134 | 5.863 | 3.803 | 6.466 | 4.864 |
Operating Margin | 40.99% | 39.47% | 34.22% | 23.46% | 34.46% | 28.05% |
Earnings before Tax (EBT) 1 | 7.257 | 8.156 | 5.794 | 4.631 | 7.876 | 5.034 |
Net income 1 | 7.171 | 8.071 | 5.704 | 4.546 | 7.789 | 4.92 |
Net margin | 42.79% | 44.66% | 33.3% | 28.04% | 41.52% | 28.37% |
EPS 2 | 3.940 | 4.435 | 3.134 | 2.498 | 4.280 | 2.703 |
Free Cash Flow 1 | -5.25 | 3.423 | 0.9124 | 8.312 | 2.748 | 4.277 |
FCF margin | -31.33% | 18.94% | 5.33% | 51.27% | 14.65% | 24.66% |
FCF Conversion (EBITDA) | - | 46.33% | 15.13% | 211.58% | 41.9% | 86.24% |
FCF Conversion (Net income) | - | 42.42% | 16% | 182.86% | 35.28% | 86.95% |
Dividend per Share | - | - | - | - | - | 0.9500 |
Announcement Date | 30/01/19 | 29/01/20 | 28/01/21 | 27/01/22 | 26/01/23 | 20/02/24 |
Balance Sheet Analysis
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 3.48 | 2.6 | 3.95 | 7.62 | 9.32 | 7.74 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -5.25 | 3.42 | 0.91 | 8.31 | 2.75 | 4.28 |
ROE (net income / shareholders' equity) | 22.2% | 45.3% | 32% | 25.5% | 43.7% | 27.6% |
ROA (Net income/ Total Assets) | 9.81% | 18.6% | 14.2% | 8.59% | 13.8% | 10.3% |
Assets 1 | 73.08 | 43.38 | 40.25 | 52.9 | 56.6 | 47.95 |
Book Value Per Share 2 | 17.60 | 9.790 | 9.790 | 9.790 | 9.790 | 9.790 |
Cash Flow per Share 2 | 1.910 | 1.430 | 2.170 | 4.190 | 5.120 | 4.250 |
Capex 1 | 0.1 | 0.2 | 0.1 | 0.05 | 0.13 | 0.08 |
Capex / Sales | 0.61% | 1.12% | 0.6% | 0.31% | 0.71% | 0.46% |
Announcement Date | 30/01/19 | 29/01/20 | 28/01/21 | 27/01/22 | 26/01/23 | 20/02/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+4.76% | 51.76M | |
+18.46% | 7.84B | |
+22.71% | 3.95B | |
-17.95% | 3.11B | |
-19.93% | 1.38B | |
-30.65% | 1.21B | |
+4.36% | 933M | |
-34.81% | 911M | |
-26.60% | 829M | |
-15.56% | 728M |
- Stock Market
- Equities
- M3V Stock
- Financials MeVis Medical Solutions AG